

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
28 April 2005 (28.04.2005)

PCT

(10) International Publication Number
WO 2005/037270 A1

(51) International Patent Classification⁷: **A61K 31/352**

Daejeon-city 305-340 (KR). **KANG, Sang-Jin** [KR/KR];
202-1502 Expo apt., Jeonmin-dong, Yuseong-gu, Dae-
jeon-city 305-728 (KR).

(21) International Application Number:
PCT/KR2004/002418

(74) Agent: **YOU ME PATENT & LAW FIRM**; Seolim Bldg.,
649-10, Yoksam-dong, Kangnam-ku, Seoul 135-080 (KR).

(22) International Filing Date:
21 September 2004 (21.09.2004)

(25) Filing Language: Korean

(26) Publication Language: English

(30) Priority Data:
10-2003-0072541 17 October 2003 (17.10.2003) KR
10-2003-0072539 17 October 2003 (17.10.2003) KR
10-2003-0072540 17 October 2003 (17.10.2003) KR
10-2003-0081596
18 November 2003 (18.11.2003) KR

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (*for all designated States except US*): **LG HOUSEHOLD & HEALTH CARE LTD.** [KR/KR];
LG Twin Tower, Yoido-dong 20, Youngdungpo-ku, Seoul 150-721 (KR).

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **JIN, Mu-Hyun** [KR/KR]; 204-1201 Sammeori apt., Dunsan-dong, Seo-gu, Daejeon-city 302-120 (KR). **LEE, Sang-Hwa** [KR/KR]; 205-302 Expo apt., Jeonmin-dong, Yuseong-gu, Daejeon-city 305-761 (KR). **PARK, Yang-Mi** [KR/KR]; 1-106 LG Employee's apt., Doryong-dong, Yuseong-gu,

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMPOSITION FOR PROMOTING SYNTHESIS OF COLLAGEN, AND COMPOSITION FOR EXTERNAL PREPARATION FOR SKIN COMPRISING THE SAME

(57) Abstract: The present invention relates to a composition for promoting collagen synthesis and a composition for external application to skin which includes the collagen synthesis promoting composition. The collagen synthesis promoting composition includes, as an effective component, at least one selected from the group consisting of compounds represented as: wherein R is hydrogen, a methoxy group, or a 3-methyl-2-butenyl group. The composition for external application to skin includes at least one collagen synthesis promoting component selected from the group consisting of compounds represented by above.



WO 2005/037270 A1

DESCRIPTION

COMPOSITION FOR PROMOTING SYNTHESIS OF COLLAGEN,
AND COMPOSITION FOR EXTERNAL PREPARATION FOR SKIN
COMPRISING THE SAME

5 TECHNICAL FIELD

The present invention relates to a composition for promoting the synthesis of collagen and a composition for external application to skin comprising the same, and more particularly, to a composition for promoting the synthesis of collagen which has an excellent collagen synthesis
10 promoting effect and a composition for external application to skin that has an anti-wrinkle effect and an effect of healing wounds.

BACKGROUND ART

Collagen is a major structural element of an extracellular matrix. It is a major structural protein generated in fibroblasts of skin and it exists in the
15 extracellular matrix. It is a significant protein that accounts for about 30 per cent of the total weight of human body protein and it has a firm triple helical structure. Collagen makes up most of the skin, tendon, bone, and organic material of teeth. Particularly, bone and dermis include a high level of collagen. In most of other body structural materials, it exists in the form of a
20 fibrous inclusion body.

Collagen is also a sort of a relatively weak immunogen partially because it shuts off a potential antigenic determinant. The helical structure also gives collagen a resistance against decomposition of protein. Main functions of collagen are to give solidness to skin, give resistance and

coherence to connective tissues, support coherence between cells, induce division and differentiation of cells (during the growth of an organism or wound healing), which was revealed by Van der Rest et al., in *Ann NY Acad Sci.*, 1990. Collagen is known to be reduced by aging and by exposure to ultraviolet rays, and this is closely related to the formation of wrinkles on the skin, which was revealed by Arthur K. Balin et al., in *Aging and the skin*, in 1989. Also, collagen plays an important role in healing of wounds. Wounds can be healed quickly without a scar by promoting the synthesis of collagen in the wounded epidermis.

Conventionally, products obtained by mixing collagen with a composition for external application to skin, such as cosmetics and ointment are brought into the market to take advantage of the skin moisturizing effect and wound healing effect of collagen. However, since the collagen in those products has large molecules, it cannot be absorbed percutaneously just by being applied to the skin. Thus, the moisturizing effect and wound healing effect cannot be anticipated. Therefore, the products do not reveal the intrinsic skin improving function and the wound healing function.

In order to solve the problem, more attention is drawn to the development of a material that can promote the synthesis of collagen. Examples of conventionally known collagen synthesis promoting materials are vitamin C, retinoic acid, a transforming growth factor (TGF) (which was disclosed by Cardinale G. et al., in *Adv. Enzymol.*, 41, p. 425, 1974), protein originated from animal placenta (JP8-231370), betulinic acid (JP8-208424), chlorella extract which promotes multiplication of fibroblasts (JP9-40523 and

JP10-36283).

However, the above-mentioned materials cannot contribute to the substantial improvement in skin function or wound healing because they have insignificant effects or they have a limited quantity of use due to safety
5 problems such as redness and irritation caused when they are applied to skin. Therefore, it is required to develop a composition for external application to skin which is safer to a human body and more effective than the conventional external skin application compositions.

10 **DISCLOSURE OF INVENTION**

TECHNICAL PROBLEM


In order to resolve the problems described above, it is an aspect of the present invention to provide a composition for promoting synthesis of collagen with an excellent collagen synthesis promoting effect.

15 It is another aspect of the present invention to provide a composition for external application to skin which has an anti-wrinkle effect and a wound healing effect.

TECHNICAL SOLUTION

To achieve the aspects, the present invention provides a composition
20 for promoting synthesis of collagen, the composition including at least one selected from the group consisting of compounds represented by the following Chemical Formula 1 as an effective compound.

Chemical Formula 1



wherein R denotes hydrogen, a methoxy group, or a 3-methyl-2-butenyl group.

5

The present invention further provides a composition for external application to skin which includes the collagen synthesis promoting composition which containing at least one selected from the group consisting of compounds represented by Chemical Formula 1.

10

ADVANTAGEOUS EFFECTS

The collagen synthesis promoting composition of the present invention can promote the synthesis of collagen in fibroblasts of skin. The external skin application composition can improve the elasticity of the skin and reduce wrinkles effectively, and it also has excellent wound healing, anti-inflammatory, and antioxidative effects.

15

DESCRIPTION OF DRAWINGS

Fig. 1 is a ^1H -Nuclear Magnetic Resonance (NMR) spectrum of xanthotoxol obtained in accordance with Example 1 of the present invention;

20

Fig. 2 is a ^{13}C - NMR spectrum of xanthotoxol obtained in accordance with Example 1 of the present invention;

Fig. 3 is a mass spectrum of xanthotoxol obtained in accordance with Example 1 of the present invention;

Fig. 4 is a ^1H -NMR spectrum of 8-hydroxybergapten obtained in accordance with Example 2 of the present invention;

5 Fig. 5 is a ^{13}C -NMR spectrum of 8-hydroxybergapten obtained in accordance with Example 2 of the present invention;

Fig. 6 is a mass spectrum of 8-hydroxybergapten obtained in accordance with Example 2 of the present invention;

10 Fig. 7 is a ^1H -NMR spectrum of prangenidin obtained in accordance with Example 3 of the present invention;

Fig. 8 is a ^{13}C -NMR spectrum of prangenidin obtained in accordance with Example 3 of the present invention; and

Fig. 9 is a mass spectrum of prangenidin obtained in accordance with Example 3 of the present invention.

15

BEST MODE


In the following detailed description, the following embodiments of the invention have been shown and described, simply by way of illustration of the best mode contemplated by the inventors of carrying out the invention. As
20 will be realized, the invention is capable of modification in various respects, all without departing from the invention. Accordingly, the drawings and description are to be regarded as illustrative in nature, and not restrictive.

The inventor(s) of the present invention were developing a composition for promoting synthesis of collagen which can reduce wrinkles

on the skin and heal wounds and a material having an excellent collagen synthesis promoting effect as an effective compound of a composition for external application to skin, when they discovered a strong collagen synthesis promoting effect from compounds represented by the following

5 Chemical Formula 1 and completed the present invention.

Chemical Formula 1



wherein R denotes hydrogen, a methoxy group, or a 3-methyl-2-butenyl group.

10

The composition for promoting the synthesis of collagen, which will be referred to as a collagen synthesis promoting composition hereafter, includes as an effective compound at least one selected from the compounds represented by Chemical Formula 1.

15 Among the compounds represented by Chemical Formula 1, a compound where R is hydrogen is xanthotoxol, i.e., 8-hydroxypsoralen; a compound where R is a methoxy group is 8-hydroxybergapten, i.e., 5-benzofuranacrylic acid and 6,7-dihydroxy-4-methoxy-,delta-lactone; and a compound where R is 3-methyl-2-butenyl group is prangenidin, i.e., 5-

20 Benzofuranacrylic acid, 6,7-dihydroxy-4-(3-methyl-2-butenyl)-delta-lactone.

Since the compounds of Chemical Formula 1 are safe to a human body and have an effect of promoting the synthesis of collagen in fibroblasts

of the skin, they are appropriate to be used for a collagen synthesis promoting composition. In addition, they have excellent effects of reducing wrinkles by improving the elasticity of the skin, as well as for healing wounds.

The compounds of Chemical Formula 1 mostly exist in the roots of umbelliferae plants and they can be acquired through various extracting
5 methods. For example, the compounds can be obtained by chopping the roots of angelica dahurica (i.e., angelica dahuricae or angelica dahurica var. formosana), which is a plant of an umbelliferae order taxonomically, into pieces, putting the pieces into water, anhydrous or hydrous low molecular
10 weight alcohol having 1 to 4 carbon atoms, ethylacetate, acetone, chloroform, or a combination thereof, heating the mixture for extraction, performing solvent fractionation, and then carrying out recrystallization.

The compounds of Chemical Formula 1 can be also acquired by first extracting imperatorin and cnidirin, which are major compounds of the
15 angelica dahurica or angelica dahurica var. formosana, to improve the extraction efficiency of the effective compound and performing Claisen rearrangement thereon.

There is no restriction in the content of the compounds of Chemical Formula 1, which is included in the collagen synthesis promoting composition suggested in the present invention. Therefore, if a strong collagen
20 synthesis promoting effect is needed, the collagen synthesis promoting composition can include the compounds up to 100 wt%. In short, the compound can be used freely within the effective content range, e.g., in the range of 0.00001 to 5 wt%.

The collagen synthesis promoting composition of the present invention can be applied to a human body in various forms. It can be dosed in an oral or parenteral method or it can be included in a liquid-type or solid-type carrier that can be admitted pharmacologically.

5 Also, the composition for external application to skin, which will be referred to as an external skin application composition hereafter, includes the compounds of Chemical Formula 1 as a collagen synthesis promoting composition. The external skin application composition is nonpoisonous to a human body and has excellent effects of restoring elasticity to skin,
10 reducing wrinkles, and healing wounds.

The external skin application composition can include the compounds of Chemical Formula 1 in the range of 0.000001 wt% to 10 wt% with respect to the entire composition weight. Preferably, it includes the compounds of Chemical Formula 1 in the range of 0.001 wt% to 10 wt% and, most
15 preferably, in the range of 0.1 wt% to 10 wt%. If the content of the compounds of Chemical Formula 1 is less than 0.000001 wt%, no remarkable effect is expected. If it exceeds 10 wt%, a further increase in the effect by the increase in the content does not appear.

The external skin application composition can be used as cosmetics
20 for reducing wrinkles on the skin and/or as a drug for healing wounds.

The external skin application composition can be prepared in the forms of powder, gel, ointment, cream or liquid, and it can be used being mixed with one or more selected from the group consisting of an antibiotic, a coupling agent, a disintegrant, a diluent, a glossing agent, a stabilizer, a

preservative, and an aromatic material.

Also, the external skin application composition can be prepared in forms of cream, foam, toilet water, cosmetic pack, skin softener, oil, foundation, makeup base, essence, soap, liquid rinse, a bathing additive, sunscreen cream, sun oil, and spray-type liquid products. It can be mixed with other general components used for preparing cosmetic compositions, such as oil, water, a surface active agent, a moisturizing agent, low molecular weight alcohol, a thickener, a chelate compound, pigment, an antiseptic, and an aromatic material.

10

MODE FOR INVENTION

The following examples further illustrate the present invention in detail but they are not to be construed to limit the scope thereof.


Example 1: Extraction of Xanthotoxol

15 1-1. Extraction of Xanthotoxol Using Methanol

1 kg dried roots of angelica dahurica or angelica dahurica var. formosana were put into 10l methanol and heated for extraction in an extractor with a Liebig condenser at 80°C for 3 hours to thereby obtain 85g of methanol extract. The methanol extract was removed from the hexane fraction through solvent fractionation. The obtained fraction was fractionated with chloroform three times to thereby obtain 9g of a chloroform fraction. From the obtained chloroform fraction, 0.3g of a fraction containing xanthotoxol was obtained through performing silica column chromatography several times. Xanthotoxol of the following Chemical Formula 2 was

obtained by performing preparative High Performance Liquid Chromatography (prep-HPLC) and recrystallization on the xanthotoxol-containing fraction. The composition and contents of the above-obtained xanthotoxol were confirmed through Nuclear Magnetic Resonance (NMR) and Mass spectroscopy. Figs. 1 and 2 show a ^1H -NMR spectrum and a ^{13}C -NMR spectrum of xanthotoxol, respectively. In the drawings, the numbers over the peaks correspond to the numbers written in chemical formulas of Figs. 1 and 2. Fig. 3 presents a mass spectrum of the xanthotoxol.

Chemical Formula 2



1-2. Extraction of Xanthotoxol Using Chloroform

1 kg dried roots of angelica dahurica or angelica dahurica var. formosana were put into 10l chloroform and heated for extraction in an extractor with a Liebig condenser at 100°C for 3 hours to thereby obtain 12g of chloroform extract. The chloroform extract was dissolved in chloroform and solvent fractionation was performed thereon with an alkali aqueous solution, which was a 0.1M NaOH aqueous solution, to thereby obtain an alkali aqueous solution soluble fraction. The alkali aqueous solution soluble fraction was neutralized with HCl. Then, with 1g of the chloroform fraction that was obtained by performing solvent fractionation with chloroform, prep-HPLC and recrystallization were carried out to thereby obtain xanthotoxol.

The composition and contents of the above-obtained xanthotoxol were confirmed through the NMR and Mass spectroscopy. The content was 99.7 wt%.

1-3. Extraction and Chemical Deformation of Imperatorin and Cnidirin
5 Using Methanol


1 kg of dried roots of angelica dahurica or angelica dahurica var. formosana were put into 10l of methanol and heated for extraction in an extractor with a Liebig condenser at 80°C for 3 hours, to thereby obtain 85g of methanol extract. The methanol extract was fractionated with chloroform three times by performing the solvent fractionation to thereby obtain 11g of a chloroform fraction. From the chloroform fraction, 7g of a fraction containing imperatorin and cnidirin, which are major components of the angelica dahurica and angelica dahurica var. formosana, were obtained through silica column chromatography. Subsequently, the Claisen rearrangement reaction was carried out by adding 25g of N,N-Diethylanilin to the fraction containing imperatorin and cnidirin and heating the mixture at 220°C for one hour. The resultant was rinsed with a 5N HCl solution and then dissolved in chloroform and maintained in a refrigerator to induce precipitation. Xanthotoxol was obtained by performing the prep-HPLC and recrystallization on the above-obtained precipitation. The composition and contents of the above-obtained xanthotoxol were confirmed through the NMR and Mass spectroscopy. The content was 99.7 wt%.

Example 2: Extraction of 8-hydroxybergapten

2-1. Extraction of 8-Hydroxybergapten Using Methanol

1 kg of dried roots of angelica dahurica or angelica dahurica var. formosana were put into 10l of methanol and heated for extraction in an extractor with a Liebig condenser at 80°C for 3 hours to thereby obtain 85g of methanol extract. The methanol extract was removed from a hexane fraction through solvent fractionation. The obtained fraction was fractionated with chloroform three times to thereby obtain 9g of a chloroform fraction. From the obtained chloroform fraction, 0.2g of a fraction containing 8-hydroxybergapten was obtained through performing silica column chromatography several times. 8-hydroxybergapten of the following Chemical Formula 3 was obtained by performing prep-HPLC and recrystallization on the fraction containing 8-hydroxybergapten. The composition and contents of the above-obtained 8-hydroxybergapten were confirmed through NMR and Mass spectroscopy. The content was 99.7 wt%. Figs. 4 and 5 show a ^1H -NMR spectrum and a ^{13}C -NMR spectrum of the 8-hydroxybergapten, respectively. In the drawings, the numbers over the peaks correspond to the numbers written in the chemical formulas of Figs. 4 and 5. Fig. 6 presents a mass spectrum of the 8-hydroxybergapten.

Chemical Formula 3



2-2. Extraction of 8-Hydroxybergapten Using Chloroform

1 kg of dried roots of angelica dahurica or angelica dahurica var. formosana were put into 10l of chloroform and heated for extraction in an extractor with a Liebig condenser at 100°C for 3 hours to thereby obtain 12g of a chloroform extract. The chloroform extract was dissolved in chloroform and solvent fractionation was performed thereon with an alkali aqueous solution, which was a 0.1M NaOH aqueous solution, to thereby obtain an alkali aqueous solution soluble fraction. The alkali aqueous solution soluble fraction was neutralized with HCl. Then, with 1g of the chloroform fraction that was obtained by performing solvent fractionation with chloroform, prep-HPLC and recrystallization were carried out to thereby obtain 8-hydroxybergapten. The composition and contents of the above-obtained 8-hydroxybergapten were confirmed through NMR and Mass spectroscopy. The content was 99.7 wt%.

2-3. Extraction and Chemical Deformation of Imperatorin and Cnidirin Using Methanol

1 kg of dried roots of angelica dahurica or angelica dahurica var. formosana were put into 10l of methanol and heated for extraction in an extractor with a Liebig condenser at 80°C for 3 hours to thereby obtain 85g of a methanol extract. The methanol extract was fractionated with chloroform three times by performing the solvent fractionation to thereby obtain 11g of a chloroform fraction. From the chloroform fraction, a 7g fraction containing imperatorin and cnidirin, which are major components of the angelica dahurica and angelica dahurica var. formosana, were obtained through silica


column chromatography. Subsequently, the Claisen rearrangement reaction was carried out by adding 25g of N,N-Diethylanilin to the fraction containing imperatorin and cnidrin and heating the mixture at 220°C for one hour. The resultant was rinsed with a 5N HCl solution and then dissolved in chloroform and maintained in a refrigerator to induce precipitation. Subsequently, 8-hydroxybergapten was obtained by performing prep-HPLC and recrystallization on the above-obtained precipitation. The composition and contents of the above-obtained 8-hydroxybergapten were confirmed through NMR and Mass spectroscopy. The content was 99.7 wt%.

10 **Example 3: Extraction of Prangenidin**

1-1. Extraction of Prangenidin Using Methanol

1 kg of dried roots of angelica dahurica or angelica dahurica var. formosana were put into 10l of methanol and heated for extraction in an extractor with a Liebig condenser at 80°C for 3 hours to thereby obtain 85g of a methanol extract. The methanol extract was removed from the hexane fraction through solvent fractionation. The obtained fraction was fractionated with chloroform three times to thereby obtain 9g of a chloroform fraction. From the obtained chloroform fraction, 0.3g of a fraction containing prangenidin was obtained through performing silica column chromatography several times. Subsequently, prangenidin of the following Chemical Formula 4 was obtained by performing prep-HPLC and recrystallization on the prangenidin-containing fraction. The composition and contents of the above-obtained prangenidin were confirmed through NMR and Mass spectroscopy. Figs. 7 and 8 show a ¹H-NMR spectrum and a ¹³C-NMR

spectrum of prangenidin, respectively. In the drawings, the numbers over the peaks correspond to the numbers written in the chemical formulas of Figs. 7 and 8. Fig. 9 presents a mass spectrum of the xanthotoxol.



5

Chemical

Formula 4

3-2. Extraction of Prangenidin Using Chloroform

1 kg of dried roots of angelica dahurica or angelica dahurica var. formosana were put into 10l of chloroform and heated for extraction in an extractor with a Liebig condenser at 100°C for 3 hours to thereby obtain 12g of chloroform extract. The chloroform extract was dissolved in chloroform and solvent fractionation was performed thereon with an alkali aqueous solution, which was a 0.1M NaOH aqueous solution, to thereby obtain an alkali aqueous solution soluble fraction. The alkali aqueous solution soluble fraction was neutralized with HCl. Then, with 1g of the chloroform fraction that was obtained by performing solvent fractionation with chloroform, prep-HPLC and recrystallization were carried out to thereby obtain prangenidin. The composition and contents of the above-obtained prangenidin were

confirmed through NMR and Mass spectroscopy. The content was 99.7 wt%.

3-3. Extraction and Chemical Deformation of Imperatorin and Cnidirin Using Methanol

5 1 kg of dried roots of angelica dahurica or angelica dahurica var. formosana were put into 10l of methanol and heated for extraction in an extractor with a Liebig condenser at 80°C for 3 hours to thereby obtain 85g of a methanol extract. The methanol extract was fractionated with chloroform three times by performing the solvent fractionation to thereby obtain 11g of a
10 chloroform fraction. From the chloroform fraction, 7g of a fraction containing imperatorin and cnidirin, which are major components of the angelica dahurica and angelica dahurica var. formosana, were obtained through silica column chromatography. Subsequently, the Claisen rearrangement reaction was carried out by adding 25g of N,N-Diethylanilin to the fraction containing
15 imperatorin and cnidirin and heating the mixture at 220°C for one hour. The resultant was rinsed with a 5N HCl solution and then dissolved in chloroform and maintained in a refrigerator to induce precipitation. Subsequently, prangenidin was obtained by performing prep-HPLC and recrystallization on the above-obtained precipitation. The composition and content of the
20 above-obtained prangenidin were confirmed through NMR and Mass spectroscopy. The content was 99.7 wt%.

Experimental Example 1: Test for Collagen Synthesis Effect of Xanthotoxol

The collagen synthesis effect of Xanthotoxol was tested by adding

Xanthotoxol to a culture broth for human fibroblasts. The quantity of the synthesized collagen was assayed by using a Procollagen Type I C-Peptide Enzyme ImmunoAssay (PICP EIA) Kit.

Xanthotoxol solution aliquots having final concentrations of 0.5 $\mu\text{g/ml}$,
5 1 $\mu\text{g/ml}$, 2 $\mu\text{g/ml}$, 5 $\mu\text{g/ml}$, and 10 $\mu\text{g/ml}$ were added to a culture media for human fibroblasts, and the fibroblasts were cultured for one day. The culture broth of each concentration was taken out and the quantity of synthesized collagen was measured with a spectrophotometer at 450nm by using the PICP EIA Kit.

10 To compare the effect of collagen synthesis, the human fibroblasts were cultured in a culture medium to which no extra element was added (i.e., a control group) and in a culture medium to which vitamin C having a final concentration of 52.8 $\mu\text{g/ml}$ was added, and the quantity of synthesized collagen was measured with respect to the two samples with the same
15 method as above.

The quantity of generated collagen was measured by using an ultraviolet ray (UV) spectrophotometer, and the increase rate of collagen generation was calculated in a relative ratio with respect to the collagen generation quantity of the control group. The result was as shown in Table
20 1.

Table 1. Collagen synthesis effect according to concentration (* number of replications=6)

Added Element	Concentration ($\mu\text{g/ml}$)	Quantity of Synthesized Collagen (Abs)	Increase Rate (%)
Control group	-	1.129 $\pm$ 0.053	-
Xanthotoxol	0.5	1.449 $\pm$ 0.039	128.36 %
Xanthotoxol	1.0	1.535 $\pm$ 0.078	135.94 %
Xanthotoxol	2.0	1.623 $\pm$ 0.084	143.75 %
Xanthotoxol	5.0	1.651 $\pm$ 0.130	146.24 %
Xanthotoxol	10.0	1.657 $\pm$ 0.112	146.81 %
Vitamin C	52.8	1.598 $\pm$ 0.145	141.57 %

As shown in Table 1, xanthotoxol has an excellent collagen synthesis effect with respect to the human fibroblasts, and the effect of using xanthotoxol was larger than the effect of using vitamin C, which is generally known to have a collagen synthesis effect.

Experimental Example 2: Test for Collagen Synthesis Effect of 8-hydroxybergapten

The quantity of synthesized collagen and the increase rate of collagen were measured with the same method as in Experimental Example 1, except that 8-hydroxybergapten was used instead of xanthotoxol. The result was as shown in Table 2.

Table 2. Collagen synthesis effect according to concentration (*
number of replications=6)

Added Element	Concentration ($\mu\text{g/ml}$)	Quantity of Synthesized Collagen (Abs)	Increase Rate (%)
Control group	-	1.310 $\pm$ 0.072	-
8-hydroxybergapten	0.5	1.590 $\pm$ 0.102	121.4
8-hydroxybergapten	1.0	1.876 $\pm$ 0.097	143.2
8-hydroxybergapten	2.0	1.949 $\pm$ 0.111	148.8
8-hydroxybergapten	5.0	1.953 $\pm$ 0.132	149.1
8-hydroxybergapten	10.0	2.008 $\pm$ 0.129	153.3
Vitamin C	52.8	1.757 $\pm$ 0.121	134.1

As shown in Table 2, 8-hydroxybergapten has an excellent collagen
5 synthesis effect with respect to the human fibroblasts, and the effect of using
8-hydroxybergapten was larger than the effect of using vitamin C, which is
generally known to have an ability to synthesize collagen.

Experimental Example 3: Test for Collagen Synthesis Effect of

Prangenidin

The quantity of synthesized collagen and the increase rate of collagen were measured with the same method as in Experimental Example 1, except that prangenidin was used instead of xanthotoxol. The result was as shown in Table 3.

Table 3. Collagen synthesis effect according to concentration (* number of replications=6)

Added Element	Concentration ($\mu\text{g/ml}$)	Quantity of Synthesized Collagen (Abs)	Increase Rate (%)
Control group	-	1.330 $\pm$ 0.083	-
Prangenidin	0.5	1.537 $\pm$ 0.099	115.6
Prangenidin	1.0	1.778 $\pm$ 0.121	133.7
Prangenidin	2.0	1.801 $\pm$ 0.135	135.4
Prangenidin	5.0	1.813 $\pm$ 0.130	136.3
Prangenidin	10.0	1.820 $\pm$ 0.204	136.8
Vitamin C	52.8	1.739 $\pm$ 0.145	130.8

As shown in Table 3, prangenidin has an excellent collagen synthesis effect with respect to the human fibroblasts, and the effect of using prangenidin was larger than the effect of using vitamin C, which is generally known to have an ability to synthesize collagen.

Experimental Example 4: Test for Anti-Wrinkle Effect

The anti-wrinkle effects of xanthotoxol, 8-hydroxybergapten, and prangenidin were tested with respect to 6-week-old hairless mice having skin wrinkles caused by radiating light. Samples were prepared by extracting xanthotoxol, 8-hydroxybergapten, and prangenidin in accordance with Examples 1 through 3 and dissolving them in 1,3-butyleneglycol to thereby prepare 5mg/ml sample solutions.

The skin wrinkles were caused by radiating light of 2 Minimum Erythema Dose (MED) to hairless mice with a solar simulator, three days a week for 10 weeks. Then, the improvement was assayed based on quality with respect to a control group of hairless mice treated with 1,3-butyleneglycol and test groups of hairless mice treated with the 5mg/ml samples for 6 weeks.

The extent of wrinkle improvement was determined with the naked bare eye and by photographing the areas treated with the samples. The test groups and the control group were compared and the result was determined in three steps: no improvement; some improvement; and remarkable improvement. The result was as shown in Table 4.

Table 4. Wrinkle Improvement effect on the skin of hairless mice
(Population of each group = 10)

Sample	No Improvement	Some Improvement	Remarkable Improvement
Control group	9	1	0
Xanthotoxol	2	5	3
8-Hydroxybergapten	0	4	6
Prangenidin	1	5	4

5 As shown in Table 4, xanthotoxol, 8-hydroxybergapten, and prangenidin have excellent anti-wrinkle effects.

Experimental Example 5: Test for Anti-Inflammatory Effect

The anti-inflammatory effect was evaluated in an ear swelling method by using 6-week-old hairless mice. The left ears of the hairless mice were used as controlled areas to be compared with the test areas, and the right ears of the hairless mice were used as the test areas. Prior to the test, both ears of all the hairless mice were measured three times. Sample solutions were prepared by extracting xanthotoxol, 8-hydroxybergapten, and prangenidin in accordance with Examples 2 and 3 and dissolving them in ethanol at 1 wt%, individually. Then, 20 μl /ear sample solutions were applied to the right ears of the hairless mice, and 20 μl /ear of ethanol was

applied to the left ear thereof. An hour later, 2 mg/ear of arachidonic acid was applied to both ears of the hairless mice. After another hour had passed, the extent of ear edema was measured by using a micrometer, three times. Also, for comparison purposes, the anti-inflammatory effect of indomethacine, which is generally known as an anti-inflammatory agent, was measured with the same method.

The anti-inflammatory effect was a ratio of a thickness of an ear in the test area to the thickness of an ear in the controlled area. It was calculated based on the following Equation 1 and presented as a damage rate. The calculation result was as shown in Table 5.

$$\text{Damage rate (\%)} = (\text{thickness of ear in test area} / \text{thickness of ear in controlled area}) \times 100$$

Equation 1

Table 5. Anti-inflammatory effect on hairless mice (Population of each group = 3)

Sample	Concentration (wt%)	Damage Rate (%)
Xanthotoxol	1	42
8-Hydroxybergapten	1	45
Prangenidin	1	40
Indomethacine	1	51

As shown in Table 5, xanthotoxol, 8-hydroxybergapten, and prangenidin have an anti-inflammatory effect as good as indomethacine, which is known as an anti-inflammatory agent.

Experimental Example 6: Test for Wound Healing Effect by Collagen

5 **Synthesis**

A wound healing effect was tested with respect to 5-week-old male rats by using a tension stiffness method that reflects the quality and quantity of restoration from wounds. The backs of the rats were shaved and wounded with a scalpel, and then the incision was sutured. Sample solutions were prepared by extracting 8-hydroxybergapten and prangenidin in accordance with Examples 2 and 3, and dissolving them in ethanol at 1 wt%, individually. The sample solutions were injected into the incisions at 0.5 ml/cm² once every day for 6 days. After 6 days, the rats were sacrificed and the skin around the wounds was removed. Three skin specimens of 1cm-wide skin flakes crossing the incision line were prepared for each individual and their tensile strength (g/cm) was measured by using a rheometer. The measured tensile strength was used as an index of the strength of the generated collagen fiber. The tensile strength of the control group, to which only ethanol without the sample therein was applied, was taken as 100% and the increase in the tensile strength was measured as a relative strength thereto. The measurement result was as shown in the following Table 6.

10
15
20

Table 6. Wound healing effect on rats

Sample	Tensile Strength (g/cm)	Strength Rate (%)
Control Group	550	100
Xanthotoxol	642	117
8-Hydroxybergapten	680	124
Prangenidin	663	121

Experimental Example 7: Test for Antioxidative Effect

5 The antioxidative effects of 8-hydroxybergapten and prangenidin were measured by using 1,1-diphenyl-2-picrylhydrazyl (DPPH). The radical scavenging activity of each sample was calculated by measuring an optical density (O.D.) at 517 nm with a spectrophotometer. Sample solutions were prepared by extracting samples, i.e., 8-hydroxybergapten and prangenidin, in

10 accordance with the methods of Examples 2 and 3 and mixing the samples in concentrations of 3 $\mu\text{g/ml}$, 5 $\mu\text{g/ml}$, 10 $\mu\text{g/ml}$, 12 $\mu\text{g/ml}$, 50 $\mu\text{g/ml}$, 80 $\mu\text{g/ml}$, and 100 $\mu\text{g/ml}$, individually. Then, experimental solutions were prepared by mixing the 500 μl aliquots of the tested sample solutions with

15 500 μl of a 1.5×10^{-4} M DPPH methanolic solution. The quantity of DPPH remaining in each experimental solution was measured 30 minutes after the preparation of experimental solutions by using the spectrophotometer at 517 nm. In order to subtract the inherent optical densities of the samples from the measurement values of the experimental solutions, the optical densities of the sample solutions of the same concentrations were also measured at

517 nm. A control solution was prepared by mixing 500 μ l of a 1.5X10⁻⁴ M DPPH methanolic solution with 500 μ l of a methanol solution and using the mixture 30 minutes after the preparation. The radical scavenging activity of each sample was calculated based on the following Equation 2.

5 Equation 2

$$\text{Radical Scavenging Activity (\%)} = 100 \times \frac{(\text{O.D. of Control Solution} - \text{O.D. of Experimental Solution})}{(\text{O.D. of Control Solution})}$$

To determine the radical scavenging activity of each sample, a coefficient of correlation (R), which is a value in connection with the radical scavenging activity, was obtained, and an IC₅₀, a value that scavenges DPPH by 50%, was calculated. Also, in order to compare the antioxidative effects, the same experiment was carried out with respect to vitamin C. The following Table 7 shows the calculated values.

15 Table 7. Antioxidative effect in the DPPH scavenging method

Sample	IC 50 (μ g/ml)	Coefficient of Correlation (R)
Xanthotoxol	24.0	0.9901
8-Hydroxybergapten	20.3	0.9910
Prangenidin	21.6	0.9941
Vitamin C	8.43	0.9935

As shown in Table 7, 8-hydroxybergapten, and prangenidin suggested

in the present invention have a superior antioxidative effect to vitamin C.

Hereafter, examples of the external skin application composition comprising the effective compound of the present invention will be presented.

Examples 4 to 6 and Comparative Example 1: Cosmetic Essence

5 Cosmetic essences having compositions shown in Table 8 were prepared.

Table 8

Composition (wt%)	Example 4	Example 5	Example 6	Comparative Example1
Xanthotoxol	1	-	-	-
8-Hydroxybergapten	-	1	-	-
Prangenidin	-	-	1	-
Propyleneglycol	10.0	10.0	10.0	10.0
Glycerine	10.0	10.0	10.0	10.0
Sodium hyaluronate aqueous solution (1%)	5.0	5.0	5.0	5.0
Ethanol	5.0	5.0	5.0	5.0
Polyoxyethylene hydrogenated castor oil	1.0	1.0	1.0	1.0
Methyl parahydroxybenzoate	0.1	0.1	0.1	0.1
Aromatic Material	0.05	0.05	0.05	0.05
Purified Water	to 100	to 100	to 100	to 100

Experimental Example 8: Test for anti-wrinkle effect of cosmetic essence based on panel survey

Panel tests were performed with respect to the cosmetic essences prepared in accordance with Examples 4 to 6 and Comparative Example 1 to
5 determine the anti-wrinkle effect of the cosmetic essences.

60 healthy females aged 35 to 50 were selected and divided into four groups, 15 subjects for each group. Then, the essences of Examples 4 through 6 and Comparative Example 1 were respectively applied to the faces of those in the first through fourth groups, once every day for three months.

10 After the three months had passed, the subjects were surveyed for the wrinkle declining effect in their skin, i.e., the anti-wrinkle effect.

The subjects were asked to evaluate the anti-wrinkle effect and improvement in the elasticity of their skin in the three steps of no improvement, some improvement, and remarkable improvement, compared
15 with the state of their skin before the experiments. The results were as shown in Table 9.

Table 9. Anti-wrinkle effect of the examples of the present invention
(Based on survey)

Sample	No Improvement	Some Improvement	Remarkable Improvement
Comparative Example 1	9	5	1
Example 4	1	8	6
Example 5	-	7	8
Example 6	-	8	7

As shown in Table 9, the anti-wrinkle effect was excellent when the
5 essences of Examples 4 to 6 of the present invention were applied.

Experimental Example 9: Test for anti-wrinkle effect of cosmetic
essence based on video analysis

Panel tests were performed with respect to 60 healthy females aged
35 to 50 with the same method as in Experimental Example 8 to determine
10 the anti-wrinkle effect of the essences prepared in accordance with
Examples 4 to 6. Then, the anti-wrinkle effects of Examples 4 to 6 were
analyzed through video analysis.

For the video analysis, replicas under eyes were extracted before and
after the experiments (Xantopren, Bayer) and skin wrinkles were analyzed
15 two-dimensionally through video analysis, and wrinkle densities were
measured.

In the video analysis, a wrinkle decrease rate was an average ratio of

wrinkle density after experiment to a wrinkle density before experiment. The measurement results were as shown in the following Table 10.

Table 10. Anti-wrinkle effect based on video analysis

5

Sample	Decrease Rate of Wrinkle Density (%)
Comparative Example 1	8
Example 4	42
Example 5	47
Example 6	42

As shown in Table 10, the wrinkle densities were decreased remarkably when the essences of Examples 4 to 6 of the present invention were applied, compared with the wrinkle density when the essence of Comparative Example 1 was used.

10

During the experiments, no skin irritation or adverse effects were found with the use of the essences of Examples 4 to 6.

Examples 7 to 9 and Comparative Example 2: Ointment for external skin application

Ointments for external skin application having compositions shown in the following Table 11 were prepared.

15

Table 11

Composition (wt%)	Example 7	Example 8	Example 9	Comparative Example 2
Xanthotoxol	2	-	-	-
8-hydroxybergapten	-	2	-	-
Prangenidin	-	-	2	-
Diethyl sebacate	8	8	8	8
Spermaceti	5	5	5	5
Polyoxyethylene Oleyletherphosphate	6	6	6	6
Sodium benzoate	0.1	0.1	0.1	0.1
Vaseline	to 100	to 100	to 100	to 100

Examples 10 to 12 and Comparative Example 3: Cosmetic cream

Cosmetic creams having compositions as shown in Table 12 were
5 prepared.

Table 12

Composition (wt%)	Example 10	Example 11	Example 12	Comparative Example 3
Xanthotoxol	0.5	-	-	-
8-hydroxybergapten	-	0.5	-	-
Prangenidin	-	-	0.5	-
Stearic acid	15.0	15.0	15.0	15.0
Cetanol	1.0	1.0	1.0	1.0
Potassium hydroxide	0.7	0.7	0.7	0.7
Glycerine	5.0	5.0	5.0	5.0
Propylene glycol	3.0	3.0	3.0	3.0
Antiseptic	0.05	0.05	0.05	0.05
Aromatic material	0.05	0.05	0.05	0.05
Purified water	to 100	to 100	to 100	to 100

Examples 13 to 15 and Comparative Example 4: Skin softener

Cosmetic creams having compositions as shown in Table 13 were

5 prepared.

Table 13

Composition (wt%)	Example 13	Example 14	Example 15	Comparative Example 4
Xanthotoxol	0.2	-	-	-
8-hydroxybergapten	-	0.2	-	-
Prangenidin	-	-	0.2	-
Ethanol	10.0	10.0	10.0	10.0
Polylauric acid polyoxyethylene sorbitan	1.0	1.0	1.0	1.0
Methyl parahydroxybenzoate	0.2	0.2	0.2	0.2
Glycerine	5.0	5.0	5.0	5.0
1,3-butylene glycol	6.0	6.0	6.0	6.0
Aromatic material	0.05	0.05	0.05	0.05
Pigment	0.05	0.05	0.05	0.05
Purified water	to 100	to 100	to 100	to 100

Examples 16 to 18 and Comparative Example 5: Nutritive lotion

Nutritive lotion having compositions as shown in Table 14 were prepared.

Table 14

Composition (wt%)	Example 16	Example 17	Example 18	Comparative Example 5
Xanthotoxol	0.1	-	-	-
8-hydroxybergapten	-	0.1	-	-
Prangenidin	-	-	0.1	-
Vaseline	2.0	2.0	2.0	2.0
Sesquioleic acid sorbitan	0.8	0.8	0.8	0.8
Polyoxyethylene oleylethyl	1.2	1.2	1.2	1.2
Methyl parahydroxybenzoate	0.1	0.1	0.1	0.1
Propylene glycol	5.0	5.0	5.0	5.0
Ethanol	3.2	3.2	3.2	3.2
Carboxyvinyl polymer	18.0	18.0	18.0	18.0
Potassium hydroxide	0.1	0.1	0.1	0.1
Pigment	0.05	0.05	0.05	0.05
Aromatic material	0.05	0.05	0.05	0.05
Purified water	to 100	to 100	to 100	to 100

Examples 19 to 21 and Comparative Example 6: Cosmetic pack

Cosmetic pack having compositions as shown in Table 15 were prepared.

Table 15

Composition (wt%)	Example 19	Example 20	Example 21	Comparative Example 6
Xanthotoxol	0.2	-	-	-
8-hydroxybergapten	-	0.2	-	-
Prangenidin	-	-	0.2	-
Glycerine	5.0	5.0	5.0	5.0
Propylene glycol	4.0	4.0	4.0	4.0
Polyvinyl alcohol	15.0	15.0	15.0	15.0
Ethanol	8.0	8.0	8.0	8.0
Polyoxyethylene oleylethyl	1.0	1.0	1.0	1.0
Methyl parahydroxybenzoate	0.2	0.2	0.2	0.2
Pigment	0.05	0.05	0.05	0.05
Aromatic material	0.05	0.05	0.05	0.05
Purified water	to 100	to 100	to 100	to 100

Examples 22 and 23 and Comparative Example 7: Skin softener for

male

Skin softeners for male having compositions as shown in Table 16 were prepared.

Table 16

Composition (wt%)	Example 22	Example 23	Example 24	Comparative Example 7
Xanthotoxol	0.1	-	-	-
8-hydroxybergapten	-	0.1	-	-
Prangenidin	-	-	0.1	-
Ethanol	55.0	55.0	55.0	55.0
PEG-40 Hydrogenated castor oil	0.5	0.5	0.5	0.5
1,3-butylene glycol	1.0	1.0	1.0	1.0
Glycereth-26	1.0	1.0	1.0	1.0
Antiseptic	0.05	0.05	0.05	0.05
Aromatic material	0.05	0.05	0.05	0.05
Purified water	to 100	to 100	to 100	to 100

5


As described above, the collagen synthesis promoting composition including at least one selected from the group consisting of xanthotoxol, 8-hydroxybergapten, and prangenidin as an effective compound has a quite

strong collagen synthesis effect in the human fibroblasts. Also, the external skin application compositions including the collagen synthesis promoting composition have excellent anti-wrinkle effects, wound healing effects, anti-inflammatory effects, and antioxidative effects.

Claims

1. A composition for promoting synthesis of collagen, comprising, as an effective component, at least one selected from the group consisting of compounds represented by:


5



wherein R is hydrogen, a methoxy group, or a 3-methyl-2-butenyl group.

10

2. A composition for external application to skin, comprising:
at least one collagen synthesis promoting component selected from the group consisting of compounds represented by:



15

wherein R is hydrogen, a methoxy group, or a 3-methyl-2-butenyl group.

3. The composition for external application to skin of claim 2, wherein the compounds represented by the chemical formula are included in

the range of 0.000001 wt% to 10 wt% with respect to the entire composition.

4. The composition for external application to skin of claim 2, wherein the composition for external application to skin is prepared in a type
5 selected from the group consisting of powder, gel, ointment, cream, and liquid.

5. The composition for external application to skin of claim 2, wherein the composition for external application to skin is prepared in a type
10 selected from the group consisting of cream, foam, toilet water, cosmetic pack, skin softener, lotion, foundation, makeup base, essence, soap, liquid rinse, a bathing additive, sunscreen cream, sun oil, and spray liquid.

6. The composition for external application to skin of claim 2,
15 wherein the composition for external application to skin is a composition for anti-wrinkle cosmetics.

7. The composition for external application to skin of claim 2, wherein the composition for external application to skin is a composition for
20 healing wounds.

FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8





FIG. 9



INTERNATIONAL SEARCH REPORT

International application No.
PCT/KR2004/002418

A. CLASSIFICATION OF SUBJECT MATTER**IPC7 A61K 31/352**

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7 A61K 31/352

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
Korean patents and applications for inventions since 1975

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
STN[Caplus, (xanthotoxol or 8-hydroxybergapten or prangenidin) and (collagen or wound healing or wrinkle)]
Pubmed

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JP P2001-131050 A (KANEBO COSMETICS INC.) 15 May 2001 See the whole document.	2 - 5
X	WO 03/072120 A1 (YANG, LIPING) 4 September 2003 See abstract and p 4.	7
A	NG et al., 'Antioxidative activity of natural products from plants', Life Sciences, 2000, Vol.66, No.8, pp.709-723 See the whole document.	1 - 7
A	ELZAHAB et al., 'Photooxygenation of some potentially skin-photosensitizing hydroxyfurocoumarins. Part2 : Xanthotoxol and bergapto!', Pharmazie, 1993, Vol.48, pp.144-145 See the whole document.	1 - 7
A	US 5360816 A (JEAN-JACQUES GOUPIL) 1 November 1994 See the whole document.	1 - 7



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

03 DECEMBER 2004 (03.12.2004)

Date of mailing of the international search report

04 DECEMBER 2004 (04.12.2004)

Name and mailing address of the ISA/KR



Korean Intellectual Property Office
920 Dunsan-dong, Seo-gu, Daejeon 302-701,
Republic of Korea

Facsimile No. 82-42-472-7140

Authorized officer

LEE, Mi Jeong

Telephone No. 82-42-481-5601



INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/KR2004/002418

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
JP P2001-131050 A	15.05.2001	None	
WO 03/072120 A1	04.09.2003	CN 1374309 A	16.10.2002
		CA 2477019 AA	04.09.2003
		KR 2004-0083461 A	01.10.2004
US 5360816 A	01.11.1994	US 5405868 A	11.04.1995
		JP 61246185 A2	01.11.1986
		GB 1573370 A	20.08.1980
		EP 0001733 A1	02.05.1979
		DE 2734823 A1	16.02.1978
		CA 1097224 A1	10.03.1981
		AU 0519004 B2	05.11.1981